NCT03624309View on ClinicalTrials.gov

Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

December 31, 2020

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Anlotinib Plus Docetaxel

Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)

DRUG

Docetaxel

Docetaxel (75mg/m2 IV d1)

Trial Locations (1)

410000

RECRUITING

Hunan Cancer hospital, Changsha

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

collaborator

Hunan Provincial People's Hospital

OTHER

lead

Hunan Cancer Hospital

OTHER